Evercore ISI Group Maintains Outperform on Altimmune, Lowers Price Target to $14

Benzinga · 3d ago
Evercore ISI Group analyst Liisa Bayko maintains Altimmune (NASDAQ:ALT) with a Outperform and lowers the price target from $17 to $14.